Oncology News and Research

RSS
CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Positive data from Onconova Therapeutics' ON 01910.Na trial for advanced MDS

Specialty pharmaceutical market: Treatment patterns and product performance

Specialty pharmaceutical market: Treatment patterns and product performance

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

New genetic approach may hold promise for sickle cell disease

New genetic approach may hold promise for sickle cell disease

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Roche Diagnostics launches new customer training center in Pleasanton, California

Roche Diagnostics launches new customer training center in Pleasanton, California

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

SAVI applicator for breast brachytherapy can be an effective therapy for breast cancer

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen announces results from first Phase 1/2 study of Nplate

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

CAM314 randomized Phase 3 clinical trial results released

CAM314 randomized Phase 3 clinical trial results released

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.